Goldman Sachs Group Inc Biocryst Pharmaceuticals Inc Transaction History

Goldman Sachs Group Inc

$596 Billion
Q1 2025

A detailed history of Goldman Sachs Group Inc transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,931,934 shares of BCRX stock, worth $21.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,931,934

Previous 1,931,934 -0.0%

Holding current value

$21.2 Million

Previous $14.5 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 09, 2025	BUY	$7.06 - $9.39 $4.52 Million - $6.02 Million	640,704 Added 49.62%	1,931,934 $14.5 Million
Q4 2024 Feb 11, 2025	SELL	$7.03 - $8.43 $7.24 Million - $8.68 Million	-1,029,299 Reduced 44.36%	1,291,230 $9.71 Million
Q3 2024 Nov 14, 2024	SELL	$6.41 - $8.69 $1.34 Million - $1.82 Million	-209,730 Reduced 8.29%	2,320,529 $17.6 Million
Q2 2024 Aug 13, 2024	BUY	$4.13 - $6.79 $2.5 Million - $4.11 Million	604,894 Added 31.42%	2,530,259 $15.6 Million
Q1 2024 May 15, 2024	BUY	$4.89 - $7.65 $736,487 - $1.15 Million	150,611 Added 8.49%	1,925,365 $9.78 Million
Q4 2023 Feb 13, 2024	BUY	$4.98 - $6.77 $1.16 Million - $1.57 Million	232,043 Added 15.04%	1,774,754 $10.6 Million
Q3 2023 May 14, 2024	SELL	$6.71 - $7.92 $1.56 Million - $1.84 Million	-232,043 Reduced 13.07%	1,542,711 $10.9 Million
Q3 2023 Nov 14, 2023	BUY	$6.71 - $7.92 $428,916 - $506,262	63,922 Added 4.32%	1,542,711 $10.9 Million
Q2 2023 May 14, 2024	BUY	$6.96 - $8.81 $2.45 Million - $3.1 Million	352,083 Added 31.25%	1,478,789 $10.4 Million
Q2 2023 Aug 14, 2023	BUY	$6.96 - $8.81 $2.45 Million - $3.1 Million	352,083 Added 31.25%	1,478,789 $10.4 Million
Q1 2023 May 14, 2024	SELL	$7.94 - $11.84 $39,604 - $59,057	-4,988 Reduced 0.44%	1,126,706 $9.4 Million
Q1 2023 May 11, 2023	SELL	$7.94 - $11.84 $39,604 - $59,057	-4,988 Reduced 0.44%	1,126,706 $9.4 Million
Q4 2022 May 14, 2024	SELL	$10.5 - $14.2 $3.54 Million - $4.79 Million	-337,461 Reduced 22.97%	1,131,694 $13 Million
Q4 2022 Feb 13, 2023	SELL	$10.5 - $14.2 $3.54 Million - $4.79 Million	-337,461 Reduced 22.97%	1,131,694 $13 Million
Q3 2022 May 14, 2024	BUY	$10.79 - $14.81 $997,459 - $1.37 Million	92,443 Added 6.71%	1,469,155 $18.5 Million
Q3 2022 Nov 10, 2022	BUY	$10.79 - $14.81 $997,459 - $1.37 Million	92,443 Added 6.71%	1,469,155 $18.5 Million
Q2 2022 May 14, 2024	SELL	$7.89 - $17.88 $3.14 Million - $7.12 Million	-398,042 Reduced 22.43%	1,376,712 $14.6 Million
Q2 2022 Aug 15, 2022	BUY	$7.89 - $17.88 $813,356 - $1.84 Million	103,087 Added 8.09%	1,376,712 $14.6 Million
Q1 2022 May 16, 2022	BUY	$11.56 - $19.76 $5.32 Million - $9.09 Million	459,965 Added 56.53%	1,273,625 $20.7 Million
Q4 2021 Feb 14, 2022	BUY	$11.18 - $15.46 $513,888 - $710,618	45,965 Added 5.99%	813,660 $11.3 Million
Q3 2021 Nov 10, 2021	BUY	$14.21 - $17.65 $10.9 Million - $13.5 Million	767,695 New	767,695 $11 Million

Others Institutions Holding BCRX

# of Institutions

293

Shares Held

177M

Call Options Held

721K

Put Options Held

489K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $2.04B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Biocryst Pharmaceuticals Inc Transaction History